medigraphic.com
Instituto Nacional de Salud Pública

2021, Number 2

<< Back Next >>

salud publica mex 2021; 63 (2)

Markers of kidney function among SARS-CoV-2 infected patients. A rapid review of the literature.

Salazar-Martínez E, Hernández-Mariano JÁ, Galván-Portillo M, Baltazar-Reyes MC, Parra-Cabrera MS, Tamayo y Orozco JA, Cupul-Uicab LA

Language: Spanish
References: 61
Page: 253-261
PDF size: 377.19 Kb.


ABSTRACT

Objective. To summarize the scientific literature on kidney abnormalities associated with SARS-CoV-2 infection. Materials and methods. It was conducted a rapid review using the Cochrane methodology. Results. Pre-existing chronic kidney disease (CKD) in SARS-CoV-2 infected patients ranged from 1-38% and acute kidney injury (AKI) ranged from 2.9- 86.4%. The prognosis of patients with SARS-CoV-2 infection was worse among those with CKD and those with normal remnant kidney function (RKF) that developed AKI. The risk of death was higher (pooled risk ratio =1.49; 95%CI: 1.09- 2.04) among SARS-CoV-2 infected patients with pre-existing CKD. The RKF markers showed alterations among severe and non-surviving SARS-CoV-2 patients; the most common marker was serum creatinine. Conclusions. The scientific evidence shows the relevance of the evaluation and permanent monitoring of the RKF in SARS-CoV-2 hospitalized patients to improve the prognosis of those with pre-existing CKD as well as the prognosis of those without CKD who develop AKI.


REFERENCES

  1. Worldometer. COVID-19 CORONAVIRUS PANDEMIC [internet]. Worldometer, 2020 [citado julio 24, 2020]. Disponible en: https://www. worldometers.info/coronavirus/

  2. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. https:// doi.org/10.1016/S0140-6736(20)30566-3

  3. Campos-Nonato I, Hernandez-Barrera L, Flores-Coria A, GomezÁlvarez E, Barquera S. Prevalencia, diagnóstico y control de hipertensión arterial en adultos mexicanos en condición de vulnerabilidad. Resultados de la Ensanut 100k. Salud Publica Mex. 2019;61(6):888-97. https://doi. org/10.21149/10574

  4. Campos-Nonato I, Hernandez-Barrera L, Pedroza-Tobías A, Medina C, Barquera S. Hipertensión arterial en adultos mexicanos: prevalencia, diagnóstico y tipo de tratamientoa. Ensanut MC 2016. Salud Publica Mex. 2018;60(3):233-43. https://doi.org/10.21149/8813

  5. Rojas-Martínez R, Basto-Abreu A, Aguilar-Salinas CA, Zarate-Rojas E, Villalpando S, Barrientos-Gutiérrez T. Prevalencia de diabetes por diagnóstico médico previo en México. Salud Publica Mex. 2018;60(3):224-32. https://doi.org/10.21149/8566

  6. Villalobos A, Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Mendoza-Alvarado LR, Flores-Luna ML, et al. Atención médica y acciones de autocuidado en personas que viven con diabetes, según nivel socioeconómico. Salud Publica Mex. 2019;61(6):876-87. https://doi. org/10.21149/10546

  7. Shamah-Levy T, Campos-Nonato I, Cuevas-Nasu L, Hernández-Barrera L, Morales-Ruán MDC, Rivera-Dommarco J, et al. Sobrepeso y obesidad en población mexicana en condición de vulnerabilidad. Resultados de la Ensanut 100k. Salud Publica Mex. 2019;61(6):852-65. https://doi. org/10.21149/10585

  8. Shamah-Levy T, Cuevas-Nasu L, Gaona-Pineda EB, Gómez-Acosta LM, Morales-Ruán MDC, Hernández-Ávila M, et al. Sobrepeso y obesidad en niños y adolescentes en México, actualización de la Encuesta Nacional de Salud y Nutrición de Medio Camino 2016. Salud Publica Mex. 2018;60(3):244-53. https://doi.org/10.21149/8815

  9. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368(1):m1091. https://doi.org/10.1136/bmj.m1091

  10. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369(1):m1985. https://doi.org/10.1136/bmj.m1985

  11. Malberti F, Pecchini P, Marchi G, Foramitti M. When a nephrology ward becomes a COVID-19 ward: the Cremona experience. J Nephrol. 2020;33(4):625-8. https://doi.org/10.1007/s40620-020-00743-y

  12. Treviño-Becerra A, Peña-Rodríguez JC, Reyes-Marín FA, Tamayo- Orozco JA. Therapeutic advances in nephrology. Gac Med Mex. 2008;144(6):509-23. Disponible en: https://www.ncbi.nlm.nih.gov/pubmed/ 19112724

  13. Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. Caution on kidney dysfunctions of COVID-19 patients. MedRxiv [preprint]. 2020. https://doi. org/10.1101/2020.02.08.20021212

  14. Garritty C, Stevens A, Gartlehner G, King V, Kamel C. Cochrane Rapid Reviews Methods G. Cochrane Rapid Reviews Methods Group to play a leading role in guiding the production of informed high-quality, timely research evidence syntheses. Syst Rev. 2016;5(184). https://doi.org/10.1186/ s13643-016-0360-z

  15. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane handbook for systematic reviews of interventions. Chichester: John Wiley & Sons, 2019.

  16. Salazar-Martínez E, Hernández-Mariano JA, Galván-Portillo M, Baltazar- Reyes MC, Parra-Cabrera MS, Tamayo y Orozco JA, et al. Suplemento-1. Resumen sobre el funcionamiento renal y alteraciones renales de pacientes infectados por SARS-CoV-2 reportadas en 30/47 artículos originales en la revisión. México, 2020 [citado octubre 15, 2020]. Disponible en: https://github.com/jahmspm/Repositorio_renal_covid19/blob/main/ MsRenal%26covid_Suplemento14oct2020_rev.pdf

  17. Aggarwal S, Garcia-Telles N, Aggarwal G, Lavie C, Lippi G, Henry BM. Clinical features, laboratory characteristics, and outcomes of patients hospitalized with coronavirus disease 2019 (COVID-19): Early report from the United States. Diagnosis. 2020;7(2):91-6. https://doi.org/10.1515/ dx-2020-0046

  18. Chen T, Dai Z, Mo P, Li X, Ma Z, Song S, et al. Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China (2019): a single-centered, retrospective study. J Gerontol Biol Sci. 2020;75(9):1788-95. https://doi.org/10.1093/gerona/glaa089

  19. de Lusignan S, Dorward J, Correa A, Jones N, Akinyemi O, Amirthalingam G, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis. 2020;20(9):1034-42. https://doi.org/10.1016/s1473-3099(20)30371-6

  20. Li X, Wang L, Yan S, Yang F, Xiang L, Zhu J, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. Int J Infect Dis. 2020;94(1):128-32. https://doi.org/10.1016/j.ijid.2020.03.053

  21. Price-Haywood EG, Burton J, Fort D, Seoane L. Hospitalization and mortality among black patients and white patients with Covid-19. N Engl J Med. 2020;382(26):2534-43. https://doi.org/10.1056/NEJMsa2011686

  22. Puelles VG, Lütgehetmann M, Lindenmeyer MT, Sperhake JP, Wong MN, Allweiss L, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590-2. https://doi.org/10.1056/NEJMc2011400

  23. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9. https://doi.org/10.1001/jama.2020.6775

  24. Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219-27. https://doi.org/10.1016/j. kint.2020.04.003

  25. Wang D, Yin Y, Hu C, Liu X, Zhang X, Zhou S, et al. Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China. Crit Care. 2020;24(188). https://doi.org/10.1186/s13054-020-02895-6

  26. Yamada T, Mikami T, Chopra N, Miyashita H, Chernyavsky S, Miyashita S. Patients with chronic kidney disease have a poorer prognosis of coronavirus disease 2019 (COVID-19): an experience in New York City. Int Urol Nephrol. 2020;52(7):1405-6. https://doi.org/10.1007/s11255-020-02494-y

  27. Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Res Care. 2020;8(1):1-9. https://doi.org/10.1136/bmjdrc-2020-001343

  28. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020;92(10):2067-73. https://doi.org/10.1002/jmv.25972

  29. Yang Q, Xie L, Zhang W, Zhao L, Wu H, Jiang J, et al. Analysis of the clinical characteristics, drug treatments and prognoses of 136 patients with coronavirus disease 2019. J Clin Pharm Ther. 2020;45(4):609-16. https:// doi.org/10.1111/jcpt.13170

  30. Yang R, Gui X, Zhang Y, Xiong Y. The role of essential organ-based comorbidities in the prognosis of COVID-19 infection patients. Expert Rev Respir Med. 2020;14(8):835-8. https://doi.org/10.1080/17476348.202 0.1761791

  31. Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. Analysis of 92 deceased patients with COVID-19. J Med Virol. 2020;92(11):2511-5. https://doi. org/10.1002/jmv.25891

  32. Deng Y, Liu W, Liu K, Fang YY, Shang J, Zhou L, et al. Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study. Chin Med J. 2020;133(11):1261-7. https://doi. org/10.1097/CM9.0000000000000824

  33. Hong KS, Lee KH, Chung JH, Shin KC, Choi EY, Jin HJ, et al. Clinical features and outcomes of 98 patients hospitalized with SARS-CoV-2 infection in Daegu, South Korea: A brief descriptive study. Yonsei Med J. 2020;61(5):431-7. https://doi.org/10.3349/ymj.2020.61.5.431

  34. Li Y, Hu Y, Yu J, Ma T. Retrospective analysis of laboratory testing in 54 patients with severe- or critical-type 2019 novel coronavirus pneumonia. Lab Invest. 2020;100(6):794-800. https://doi.org/10.1038/s41374-020-0431-6

  35. Pei G, Zhang Z, Peng J, Liu L, Zhang C, Yu C, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020;31(6):1157-65. https://doi.org/10.1681/asn.2020030276

  36. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-81. https://doi.org/10.1016/s2213-2600(20)30079-5

  37. Yao Q, Wang P, Wang X, Qie G, Meng M, Tong X, et al. A retrospective study of risk factors for severe acute respiratory syndrome coronavirus 2 infections in hospitalized adult patients. Pol Arch Intern Med. 2020;130(5):390-9. https://doi.org/10.20452/pamw.15312

  38. Zhao XY, Xu XX, Yin HS, Hu QM, Xiong T, Tang YY, et al. Clinical characteristics of patients with 2019 coronavirus disease in a non-Wuhan area of Hubei Province, China: a retrospective study. BMC Infect Dis. 2020;20(311). https://doi.org/10.1186/s12879-020-05010-w

  39. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829-38. https://doi.org/10.1016/j.kint.2020.03.005

  40. Wang K, Zuo P, Liu Y, Zhang M, Zhao X, Xie S, et al. Clinical and laboratory predictors of in-hospital mortality in patients with COVID-19: a cohort study in Wuhan, China. Clinical Infect Dis. 2020:ciaa538. https://doi. org/10.1093/cid/ciaa538

  41. Petrilli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369(1):m1966. https://doi.org/10.1136/bmj.m1966

  42. Chen Y, Guo Y, Pan Y, Zhao ZJ. Structure analysis of the receptor binding of 2019-nCoV. Biochem Biophys Res Commun. 2020;525(1):135-40. https://doi.org/10.1016/j.bbrc.2020.02.071

  43. Chan VW, Chiu PK, Yee CH, Yuan Y, Ng CF, Teoh JY. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol. 2020. https://doi. org/10.1007/s00345-020-03246-4

  44. Chen L, Guo C. Focus on kidney disease among the coronavirus disease 2019 patients: A comparative perspective between China, Italy and the United States. Int J Clin Pract. 2020;74(9):e13561. https://doi.org/10.1111/ ijcp.13561

  45. Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. Int J Antimicrob Agents. 2020;56(2):106024. https:// doi.org/10.1016/j.ijantimicag.2020.106024

  46. Ng JJ, Luo Y, Phua K, Choong A. Acute kidney injury in hospitalized patients with coronavirus disease 2019 (COVID-19): A meta-analysis. J Infect. 2020;81(4):647-79. https://doi.org/10.1016/j.jinf.2020.05.009

  47. Rowland B, Kunadian V. Challenges in the management of older patients with acute coronary syndromes in the COVID-19 pandemic. Heart. 2020;106(17):1296-301. https://doi.org/10.1136/heartjnl-2020-317011

  48. Sankrityayan H, Kale A, Sharma N, Anders HJ, Gaikwad AB. Evidence for use or disuse of renin-angiotensin system modulators in patients having COVID-19 with an underlying cardiorenal disorder. J Cardiovasc Pharmacol Ther. 2020;25(4):299-306. https://doi. org/10.1177/1074248420921720

  49. Soleimani M. Acute kidney injury in SARS-CoV-2 infection: Direct effect of virus on kidney proximal tubule cells. Int J Mol Sci. 2020;21(9):3275. https://doi.org/10.3390/ijms21093275

  50. Renu K, Prasanna PL, Abilash VG. Coronaviruses pathogenesis, comorbidities and multi-organ damage: A review. Life Sci. 2020;255(1):117839. https://doi.org/10.1016/j.lfs.2020.117839

  51. Zhu J, Ji P, Pang J, Zhong Z, Li H, He C, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. J Med Virol. 2020;92(10):1902- 14. https://doi.org/10.1002/jmv.25884

  52. Oyelade T, Alqahtani J, Canciani G. Prognosis of COVID-19 in patients with liver and kidney diseases: An early systematic review and meta- Analysis. Trop Med Infect Dis. 2020;5(2):80. https://doi.org/10.3390/tropicalmed5020080

  53. Zhu J, Zhong Z, Ji P, Li H, Li B, Pang J, et al. Clinicopathological characteristics of 8697 patients with COVID-19 in China: a meta-analysis. Fam Med Community Health. 2020;8(2):e000406. https://doi.org/10.1136/ fmch-2020-000406

  54. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and multiorgan response. Curr Probl Cardiol. 2020;45(8):100618. https://doi. org/10.1016/j.cpcardiol.2020.100618

  55. Salerno M, Sessa F, Piscopo A, Montana A, Torrisi M, Patane F, et al. No autopsies on COVID-19 deaths: A missed opportunity and the lockdown of science. J Clin Med. 2020;9(5):1472. https://doi.org/10.3390/jcm9051472

  56. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? Am J Physiol Renal Physiol. 2020;318(6):1454-62. https:// doi.org/10.1152/ajprenal.00160.2020

  57. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19: A systematic review. Life Sci. 2020;254(1):117788. https://doi.org/10.1016/j.lfs.2020.117788

  58. Fogarty H, Townsend L, Ni Cheallaigh C, Bergin C, Martin-Loeches I, Browne P, et al. COVID19 coagulopathy in Caucasian patients. Br J Haematol. 2020;189(6):1044-9. https://doi.org/10.1111/bjh.16749

  59. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. https://doi.org/10.1016/S0140- 6736(20)30628-0

  60. Panigrahy D, Gilligan MM, Huang S, Gartung A, Cortés-Puch I, Sime PJ, et al. Inflammation resolution: a dual-pronged approach to averting cytokine storms in COVID-19? Cancer Metastasis Rev. 2020;39(2):337-40. https://doi.org/10.1007/s10555-020-09889-4

  61. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. Work Group Membership. Kidney Int Supp. 2012;2(1):2. https://doi.org/10.1038/kisup.2012.2




2020     |     www.medigraphic.com